Core Viewpoint - The report presented at the AASLD annual meeting is a significant showcase of the company's progress in innovative drug development for hepatitis B treatment, aimed at gaining international attention in the field of hepatology and fostering friendly international exchanges and discussions [1] Group 1 - The company is committed to steadily advancing the clinical research and development of innovative hepatitis B drugs [1] - The company will fulfill its obligation to disclose information regarding the progress of innovative drugs in a timely manner, in accordance with regulations [1]

Core Viewpoint - Guangshengtang (300436) forecasts a net profit attributable to shareholders of -170 million to -240 million yuan for the year 2025, indicating a challenging financial outlook due to high R&D and management expenses [1] Group 1: Financial Performance - The company expects a net profit loss between -170 million and -240 million yuan for 2025 [1] - The high level of R&D and management expenses is attributed to significant prior fixed asset investments [1] Group 2: R&D and Clinical Trials - Guangshengtang continues to adhere to its innovative drug development strategy, with ongoing investments in R&D to expedite clinical research [1] - The Phase III clinical trial for the hepatitis B treatment drug GST-HG141 has successfully enrolled 526 participants, meeting the planned enrollment target [1] - The company anticipates completing the total enrollment by mid-February, with a possibility of slightly exceeding the original target [1] Group 3: Asset Management - The company has conducted impairment tests on intangible assets, inventory, and fixed assets at the end of the reporting period, and has made provisions for any identified impairments [1]

Economic Performance - In 2025, Ningde's GDP reached 425.17 billion yuan, growing by 7.5% year-on-year, surpassing the national average growth rate [2] - The primary industry added value was 43.04 billion yuan (3.9% growth), the secondary industry 232.28 billion yuan (10.5% growth), and the tertiary industry 149.85 billion yuan (3.6% growth) [2] - Industrial value added increased by 11.4% for the year, with significant contributions from lithium battery, new energy vehicles, stainless steel materials, and copper materials, which grew by 16.8% [3] Policy and Investment - Continuous policy support has stimulated consumption, with total retail sales of consumer goods reaching 99.28 billion yuan, a 4.1% increase [4] - Fixed asset investment, excluding real estate, grew by 1.4%, supported by infrastructure projects like highways and nuclear power plants [4] - High-tech industry investment rose by 13.2%, significantly outpacing overall fixed asset investment growth [7] Trade and Logistics - Ningde's total import and export value reached 162.96 billion yuan, a 10.4% increase, with exports at 113.30 billion yuan (12.6% growth) and imports at 49.66 billion yuan (5.6% growth) [5] Innovation and Industry Transformation - Ningde has been recognized as a global top 100 innovation cluster, with a focus on modern industrial transformation [6] - The city introduced measures to support R&D investment, leading to a 20.4% increase in R&D expenses among large industrial enterprises [7] - The clean energy sector saw significant investments, with solar power investment growing by 76.3% and wind power by 42.7% [7] Social and Economic Welfare - The total revenue of large-scale industrial enterprises reached 851.23 billion yuan, a 19.3% increase, with profits growing by 10.2% [8] - Social welfare spending reached 37.36 billion yuan, accounting for 81.5% of the general public budget, with notable increases in social security and health expenditures [8] - The average disposable income for residents was 39,204 yuan, a 5.4% increase, reflecting improved living standards [9]

Core Viewpoint - The current diagnosis rate for chronic hepatitis B in China is approximately 22%, and the treatment rate is about 15%, indicating a significant gap compared to the targets set in the "Action Plan for the Prevention and Control of Viral Hepatitis (2025-2030)" which aims for an 80% diagnosis and treatment rate by 2030 [1] Group 1 - The integration of the "screen-diagnose-treat" system is expected to significantly improve the management coverage and accessibility of treatment for chronic hepatitis B patients [1] - The advancement in this integrated system is anticipated to have a positive impact on the hepatitis B drug market [1]

历年净利、扣非情况(亿元) 1 (亿元) 0.148 0 -0.34 -1.27 -1.56 -1 -2.05 -3.48 -2 -3 -4 2020 2021 2023 2022 2024 2025E 归母净利润 扣非净利润 制图数据来自恒生聚源数据库 历年净利、扣非同比增长情况(%) 500 55-16 --- 31:15 -- 0 38.01 % -335.33 -266.19'-173.61 -500 2021 2020 2022 2023 2024 2025E ¬○- 归母净利润同比增长率 -○- 扣非净利润同比增长率 中证智能财讯广生堂（300436）1月30日晚间披露2025年度业绩预告，预计2025年归母净利润亏损1.7亿元至2.4亿元，上年同期亏损1.56亿元；扣非净利润亏 损1.78亿元至2.48亿元，上年同期亏损2亿元。以最新收盘价计算，市净率（LF）约41.43倍，市销率（TTM）约36.83倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 资料显示，公司秉承"广播仁爱·关注民生"的企业使命，坚定为人类的肝脏健康提供科学解决方案的梦想，坚定不移推动创新药物研发，实 ...

南财智讯1月30日电，广生堂发布2025年度业绩预告，预计2025年全年归属于上市公司股东的净利润为 亏损1.70亿元—2.40亿元；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为亏损 1.78亿元—2.48亿元。本报告期内，公司业绩亏损主要影响原因如下：1、报告期内，公司始终坚持创新 药发展战略，持续研发投入以快速推进创新药临床研究，且受前期固定资产投资较大等因素影响，公司 研发费用和管理费用保持在较高水平。截止目前，在研乙肝治疗一类创新药奈瑞可韦GST-HG141的III 期临床试验已完成526例受试者入组，达到临床方案设定的计划目标入组数，后续将继续推进受试者入 组工作，预计于2026年2月中旬完成全部入组，最终入组人数可能在原计划目标基础上有少部分增加。 创新药研发周期长，投入大，风险高，容易受到多方面因素的影响，临床研究存在研究进度和结果不及 预期甚至失败的风险，后续能否获得批准存在不确定性。敬请广大投资者谨慎决策，注意防范投资风 险。2、公司基于谨慎性原则，对报告期末合并报表范围内无形资产、存货、固定资产等资产进行减值 测试，对发生减值的资产计提减值准备。3、报告期内，预计非经常 ...

Financial Performance - The company expects a net loss of between 170 million and 240 million yuan for the fiscal year 2025, compared to a loss of 156.30 million yuan in the same period last year[3] - The net loss after deducting non-recurring gains and losses is projected to be between 177.50 million and 247.50 million yuan, compared to a loss of 199.54 million yuan in the previous year[3] - The company anticipates a reduction of approximately 35.73 million yuan in non-recurring gains and losses, primarily due to a significant decrease in government subsidies[6] Investment and Development - The primary reason for the loss is the ongoing investment in innovative drug development, with significant R&D and management expenses due to prior fixed asset investments[5] - The clinical trial for the innovative hepatitis B treatment drug GST-HG141 has enrolled 526 participants, meeting the planned target, with full enrollment expected by mid-February 2026[5] Asset Management - The company is conducting impairment tests on intangible assets, inventory, and fixed assets, with provisions for impairment being made[6] Caution for Investors - The final financial data for the fiscal year 2025 will be disclosed in the annual report, and investors are advised to exercise caution[7]

Core Viewpoint - The company emphasizes the significant unmet clinical needs in the treatment of chronic hepatitis B, highlighting the market opportunities presented by the Chinese government's action plan for viral hepatitis prevention and treatment from 2025 to 2030 [1] Group 1: Market Opportunity - There is a large global patient base for chronic hepatitis B, indicating substantial unmet clinical demand [1] - The Chinese action plan aims for a diagnosis rate of over 80% for chronic hepatitis B patients and an antiviral treatment rate of over 80% for newly reported patients by 2030, creating a favorable environment for innovative drug development [1] Group 2: Company Strategy - The company is committed to addressing the significant unmet clinical needs in hepatitis B treatment and is actively advancing the clinical development of related innovative drugs [1] - The company aims to validate the product's value with confirmed clinical data and apply for market approval as soon as possible, expressing confidence in the market post-launch [1] Group 3: R&D Challenges - The research and development cycle for innovative drugs is long, requires substantial investment, and carries high risks [1]

广生堂（300436.SZ）1月28日在投资者互动平台表示，GST-HG141的III期临床整体入组进度已顺利过 半。公司团队正持续高效推进患者招募入组工作，全力保障临床进展，力争尽早达成计划入组目标。后 续重要进展公司将及时履行信息披露，敬请关注。 每经AI快讯，有投资者在投资者互动平台提问：公司GST-HG141作为全球首个进入III期的II型核心蛋白 变构调节剂，目前全国50余家临床中心入组进度是否已超50%？后续入组是否会提前完成？ （记者 张明双） ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300436 | 广生堂 | 105.01 | 14.00% | 21.58万 | | 22.03亿 | | 300765 | 新诺威 | 46.21 | 12.90% | 23.06万 | | 10.27亿 | | 688428 | 诺诚健华 | 20.39 | 2.05% | 6.96万 | | 1.41亿 | | 300401 | 化园生物 | 17.71 | 1.84% | P 29.42万 | | 5.24亿 | | 688192 | 迪哲医药 | 58.96 | 1.78% | 2.60万 | | 1.52亿 | | 002099 | 海翔药业 | 6.35 | 1.28% | 33.69万 | | 2.14亿 | | 688578 | 文力斯 | 101.30 | 1.25% | 4.40万 | | 4.40 乙 | | 300573 | 兴齐眼药 | 72.10 | 1.22% | 8.25万 | | 5.96亿 | ...